WO2004072016A1 - アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 - Google Patents
アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 Download PDFInfo
- Publication number
- WO2004072016A1 WO2004072016A1 PCT/JP2004/000893 JP2004000893W WO2004072016A1 WO 2004072016 A1 WO2004072016 A1 WO 2004072016A1 JP 2004000893 W JP2004000893 W JP 2004000893W WO 2004072016 A1 WO2004072016 A1 WO 2004072016A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydroxy
- ethoxy
- methylethylamino
- hydroxyphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/32—Separation; Purification; Stabilisation; Use of additives
- C07C253/34—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Definitions
- the present invention relates to a novel amino alcohol derivative having an iS 3 -adrenoceptor stimulating activity, a pharmaceutical composition containing the same and a use thereof.
- the jS- adrenergic receptor sympathetic, beta have / 3 2 and; 3 3 Classified Ru 3 subtypes as exist, they are distributed to specific in vivo tissue, the function-specific, respectively It is known to have.
- iS-adrenergic receptors are mainly present in the heart, and stimulation via these receptors causes an increase in heart rate and cardiac contractility.
- i3 2 - adrenergic receptors are mainly vessels present in bronchial and uterine smooth muscle, stimulation via the receptor, leads to their respective vessels and bronchodilation and inhibition of uterine contraction.
- This many iS i-adrenergic receptor agonists so far and] 3 2 - adrenoceptor stimulants have been developed, cardiotonic, is subjected to medical as bronchodilators and threatened flow-preventing preterm delivery agent.
- Non-Patent Document 1 Non-Patent Documents 2 and 3, Non-patent document 4
- stimulation of the receptor to decompose fat promote heat production, lower blood glucose
- antihyperlipidemic triglyceride lowering, cholesterol lowering, HDL
- antidepressant action e.g., Non-patent Document 2, Non-patent Document 5, Non-patent Document 6, Non-patent) Reference 7
- Non-patent Document 2 Non-patent Document 5
- Non-patent Document 6 Non-patent
- i3 3 - adrenergic receptor agonist obesity, diabetes, diseases resulting from hyperlipemia, depression, the biliary tract hypermotility, treatment or prevention of such dysuria or diseases resulting from gastrointestinal hyperactivity.
- 3 3 Adrenergic receptor agonists, but many of them are increasing heart rate, muscle tremor, and low potassium. arm viremia such as / 3 1 receptor and / or
- R a is optionally substituted by halogen, hydroxy, ⁇ - 6 alkoxy, C, _ 6 alkyl, nitro, Shiano, hydroxymethyl, triflumizole Ruo Russia methyl
- R f represents (R f is hydrogen or alkyl) one or more substituted with a substituent is phenylene optionally Le group selected from the group Ru Tona;
- R b represents hydrogen or alkyl;
- RC is Shiano R d and R e independently represent hydrogen, 6 alkyl, —C 0 2 , or tetrazole-5 ⁇ r or 1C ⁇ 2 R g, where R s is hydrogen or C 6 alkyl; H, —CC ⁇ C— 6 alkyl, cyano, tetrazole-5-yl, halogen, trifluoromethyl or C 6 alkoxy] is disclosed (for example, see Patent Document 1) ,) 3 3 - stimulatory effect
- human 3 3 - shows a potent stimulatory effect on adrenergic receptors, preferably jS - and ⁇ or) 8 2 - was reduced in Adorenarin receptor stimulating effect, intensively for new compounds result of extensive research, ⁇ amino alcohol derivative represented by the general formula (I) is surprisingly one contact Yopi Z or / 3 2 - adrenergic phosphate receptor potent than the human Iotaderuta 3 - adrenoceptor They have found that they have a body stimulating action, and have completed the present invention.
- the present invention provides a compound represented by the general formula (I):
- R 1 and R 2 are each independently a hydrogen atom or a lower alkyl group
- R 3 , R 4 , R 5 and R 6 are each independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
- R 7 and R 8 each independently represent a hydrogen atom, a halogen atom, a lower alkyl group, a halo lower alkyl group, a hydroxy lower alkyl group, a cycloalkyl group, a heterocycloalkyl group, a lower alkoxy group, a di ( Lower alkyl) amino group, cyclic amino group, di (lower alkyl) amino lower alkyl group, aryl group, arylo group Xy, aralkyloxy, heteroaryl, cyano, hydroxyl, lower acyl, lower alkylsulfanyl, lower alkylsulfonyl, carbonyl, lower alkoxy carbonyl or aralkyloxycarbonyl; Represent or, when R 7 and R 8 are adjacent, they combine to form 10— (CH 2 ) m —O—, 10— (CH 2 ) n — or 1 (CH 2 ) p— And
- n an integer of 1 to 3
- n an integer of 2 to 4
- p represents an integer of 3 to 5;
- R 9 is — C (O) -R 10 , — A 1 — C (O) -R 10 , O—A 2 -C (O) -R 10 or tetrazo-l-5- ,
- R 1Q represents a hydroxyl group, a lower alkoxy group, an aralkyloxy group, or — NRHR 12 ,
- R 11 and R 12 each independently represent a hydrogen atom, a lower alkyl group, a carboxy lower alkyl group or a lower alkoxycarbonyl lower alkyl group, or R 11 and R 12 represent a nitrogen atom to which they are bonded; Together with the atom to form a cyclic amine,
- a 1 is a lower alkylene group or a lower alkenylene group
- a 2 is a lower alkylene group
- the present invention relates to a pharmaceutical composition containing, as an active ingredient, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.
- the present invention relates to an obesity, diabetes, hyperlipidemia, depression, dysuria containing a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.
- the present invention relates to a therapeutic or prophylactic agent for a disease caused by gallstones and hyperbiliary hypermotility, or a disease caused by increased digestive tract function.
- the present invention the expressed or compounds by formula (I) and its pharmacologically acceptable salt, 3 3 - Anti fertilizer Mankusuri non adrenergic receptor agonists, anti At least one selected from diabetic drugs, antihyperlipidemic drugs and dysuria drugs And pharmaceuticals comprising a combination thereof.
- the present invention provides a method for treating or preventing obesity, diabetes, hyperlipidemia, depression, dysuria, a disease derived from gallstone and hyperbiliary motility, or a disease derived from increased gastrointestinal function.
- the present invention also relates to the use of the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof for producing an agent.
- the present invention provides a method for treating or preventing obesity, diabetes, hyperlipidemia, depression, dysuria, a disease derived from gallstone and hyperbiliary motility, or a disease derived from increased gastrointestinal function.
- the method includes a step of administering an effective amount of the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof.
- the following terms have the following meanings unless otherwise specified.
- Halogen atom represents a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and is preferably a fluorine atom or a chlorine atom.
- lower alkyl group means a linear or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isoptyl, sec-butyl. Group, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, hexyl, isohexyl And so on.
- the lower alkyl group in R 1 R 2 , R 3 , RR 5 and R 6 is preferably an alkyl group having 1 to 4 carbon atoms, and more preferably a methyl group.
- the lower alkyl group for R 7 , R 8 and R 9 is preferably an alkyl group having 1 to 4 carbon atoms, more preferably a methyl group, an ethyl group, a propyl group or an isopropyl group.
- Halo lower alkyl group means a lower alkyl group substituted with one to three of the same or different halogen atoms, such as trifluoromethyl group, 2-chloroethyl group, and 2-fluoroethyl. Groups, 2,2,2-trifluoroethyl group, 2,2,2-trichloroethyl group, and the like, and preferably a trifluoromethyl group.
- “Hydroxy lower alkyl group” means a lower alkyl group substituted with a 7K acid group, such as hydroxymethyl group, 2-hydroxyethyl group, and 1-hydroxy group. Examples thereof include an ethyl group, a 3-hydroxypropyl group, and a 4-hydroxybutyl group, and a hydroxymethyl group is preferable.
- Cycloalkyl group means a saturated cyclic hydrocarbon group having 3 to 7 carbon atoms, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentylyl group, a cyclohexyl group, and a cycloheptyl group. And preferably a cyclopentyl group or a cyclohexyl group.
- Heterocycloalkyl group means a 3- to 7-membered saturated heterocyclic group containing an oxygen atom or a sulfur atom in the ring, and includes, for example, a tetrahydrofuryl group, a tetrahydric phenyl group, and a tetrahydrovinylanyl group.
- “Lower alkoxy group” means a straight-chain or branched-chain alkoxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy. Group, tert-butoxy group, pentyloxy group, hexyloxy group and the like.
- the lower alkoxy group for R 3 , R 4 , R 5 and R 6 is preferably an alkoxy group having 1 to 4 carbon atoms, and more preferably a methoxy group.
- the lower alkoxy group for R 7 , R s and R 9 is preferably an alkoxy group having 1 to 4 carbon atoms, more preferably a methoxy group, an ethoxy group, a propoxy group or an isopropoxy group.
- the lower alkoxy group for R 1 Q is preferably an alkoxy group having 1 to 4 carbon atoms, and more preferably an ethoxy group, a propoxy group, an isopropoxy group or a butoxy group.
- Di (lower alkyl) amino group means an amino group disubstituted with a lower alkyl group, and includes, for example, a dimethylamino group and a getylamino group.
- di (lower alkyl) amino lower alkyl group means a lower alkyl group substituted with a di (lower alkyl) amino group, and includes, for example, a dimethylaminomethyl group.
- “Lower acetyl group” means a group represented by (lower alkyl) —CO—, for example, acetyl group, propionyl group, butyryl group, isoptyryl group, pivaloyl group, valeryl group, isovaleryl group and the like. And is preferably an acetyl group.
- “Lower alkylsulfanyl group” means a group represented by (lower alkyl) 1 S—, for example, methylsulfanyl group, ethylsulfanyl group, propyls Examples thereof include a ruphanyl group, an isopropylsulfanyl group, a butylsulfanyl group, a pentylsulfanyl group, and a hexylsulfanyl group, and a methylsulfanyl group or an ethylsulfanyl group is preferable.
- “Lower alkylsulfonyl group” means a group represented by (lower alkyl) 1 S ⁇ 2 —, for example, methanesulfonyl group, ethanesulfonyl group, propanesulfonyl group, butanesulfonyl group, pensulfonyl group And a hexanesulfonyl group, preferably a methanesulfonyl group.
- “Lower alkoxycarbonyl group” means a group represented by (lower alkoxy) —CO—, for example, methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group, Isobutoxycarbonyl group, sec-butoxycarbonyl group, tert-butoxycarbonyl group, pentyloxycarbonyl group, hexyloxycarbonyl group, etc., and preferably methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group.
- aryl group is an unsubstituted or group consisting of the following: independently from a halogen atom, a lower alkyl group, an octa-lower alkyl group, a lower alkoxy group, a hydroxyl group, a carboxy group and a lower alkoxycarbonyl group.
- An aromatic hydrocarbon group having 6 to 14 carbon atoms which is substituted with one to three selected groups, such as phenyl, 2-fluorophenyl, 3-fluorophenyl, Monofluorophenyl group, 2-chlorophenyl group, 3,5-dichlorophenyl group, 4-methylphenyl group, 4-trifluoromethylphenyl group, 2-methoxyphenyl group, 4-methoxyphenyl group, 4-hydroxy Phenyl, 4-carboxyphenyl, 4-methoxycarbonylphenyl, naphthyl, anthryl, phenanthryl, and the like.
- a Le group such as phenyl, 2-fluorophenyl, 3-fluorophenyl, Monofluorophenyl group, 2-chlorophenyl group, 3,5-dichlorophenyl group, 4-methylphenyl group, 4-trifluoromethylphenyl group, 2-methoxyphenyl group, 4-methoxyphenyl group, 4-hydroxy Ph
- Aryloxy group means a group represented by (aryl) _ ⁇ , for example, phenoxy group, 2-fluorophenoxy group, 3-fluorophenoxy group, 4-fluorophenoxy group Group, 2-chlorophenoxy, 4-chlorophenoxy, 3,5-dichlorophenoxy, 4-methylphenoxy, 4-trifluoromethylphenoxy, 2-methoxyphenoxy, 4-methoxyphenoxy Group, 2 -Hydroxyphenoxy group, 4-hydroxypropyloxy group, 4-methoxycarbonyloxyphenoxy group, naphthyloxy group, anthroxy group, phenanthroxy group, etc., and preferably phenoxy group, 4-fluorophenoxy group.
- Alkyloxy group means a lower alkoxy group substituted with an aryl group, for example, benzyloxy group, phenethyloxy group, 3-phenylpropyloxy group, 2-fluorobenzyloxy group, and 3-fluorooxybenzyl group.
- Benzyloxy group 4-fluorobenzoyl group, 2-chlorobenzoyl group, 3,5-dicyclobenzyloxy group, 4-methylbenzyloxy group, 4-trifluoromethylbenzyloxy group, 2-methoxybenzyl And a 4-hydroxybenzyloxy group, a 4-hydroxybenzyloxy group, a 4-methoxycarbonyldibenzyloxy group, and the like, and preferably a benzyloxy group.
- the “aralkyloxycarbonyl group” means a group represented by (aralkyloxy) -CO—, for example, a benzyloxycarbonyl group, a phenethyloxyl-proponyl group, a 3_phenylpropyloxycarbonyl group, and the like. And preferably a benzyloxycarbonyl group.
- Heteroaryl group means; Means a 5- or 6-membered aromatic heterocyclic group containing up to 5 carbon atoms and 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur atoms Provided that these rings do not include adjacent oxygen atoms and Z or sulfur atoms.
- Specific examples of the heteroaryl group include, for example, a pyrrolyl group, a furyl group, a chenyl group, an imidazolyl group, a pyrazolyl group,
- aromatic heterocyclic groups 1, 2, 4-monotriazolyl group, oxazolyl group, thiazolyl group, isoxazolyl group, tetrazolyl group, pyridyl group, pyrazinyl group, pyrimidyl group and the like. All regioisomers of these aromatic heterocyclic groups are possible (eg, 2-pyridyl, 3-pyridyl, 4-pyridyl, etc.). These aromatic heterocycles are optionally selected independently from the group consisting of halogen atoms, lower alkyl groups, halo-lower alkyl groups, lower alkoxy groups, hydroxyl groups, carboxy groups and lower alkoxycarbonyl groups. It can be substituted with up to 3 groups.
- Preferred hete A loaryl group is an imidazolyl, pyrazolyl, thiazolyl, pyridyl, pyrazinyl or pyrimidyl group.
- Carboxy lower alkyl group means a lower alkyl group substituted with a carboxy group, for example, carboxymethyl group, 2-carboxyl, 1-carboxyl, 3-carboxyl, 4-carboxyl, And a carboxymethyl group.
- “Lower alkoxycarbonyl lower alkyl group” means a lower alkyl group substituted with a lower alkoxycarbonyl group, for example, a methoxycarbonylmethyl group, an ethoxycarbonylmethyl group, a propoxycarbonylmethyl group, an isopropoxycarbonylmethyl group.
- it is a methoxycarbonylmethyl group, an X-methoxycarbonylmethyl group, a propoxyl-proponylmethyl group, an isopropoxycarbonylmethyl group, or a butoxycarbonylmethyl group.
- Cyclic amine or cyclic amino group means a 5- to 7-membered saturated cyclic amino group which may contain an oxygen atom in the ring, for example, a pyrrolidyl group, a piperidyl group, a morpholinyl group and the like. .
- the “lower alkylene group” means a straight or branched divalent saturated hydrocarbon chain having 1 to 4 carbon atoms, such as —CH 2 —, one CH 2 CH 2 —, —CH (CH 3 ) one, one HQC ri (Gl Uno-1!) "1 3 ) 2---v.Cn 2 h. 3 )--1 CJTTLO — And the like, and preferably —CH 2 —.
- the biphenyl bond is a phenyl ring to which R 3 , R 4 , R 5 or R 6 is bonded, and a phenyl ring to which R 7 , R 8 or R 9 is bonded. Represents a bond between
- the present invention relates to a compound in which each asymmetric carbon atom has an R configuration, a compound having an S configuration, And any combination thereof.
- the racemates, racemic mixtures, single enantiomers, and diastereomeric mixtures thereof are also included in the scope of the present invention.
- the present invention includes any of the cis isomers, trans isomers, and mixtures thereof. I do.
- the compound represented by the general formula (I) of the present invention includes hydrates and solvates with pharmaceutically acceptable solvents such as ethanol.
- the compound represented by the general formula (I) of the present invention can exist in the form of a salt.
- salts include addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid, formic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
- Addition salts with organic acids such as acid, propionic acid, cunic acid, succinic acid, tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, malic acid, carbonic acid, dalminic acid, and aspartic acid
- salts with inorganic bases such as sodium, potassium, potassium and potassium salts, and salts with organic bases such as triethylamine, piperidine, morpholine, lysine and ethylenediamine.
- prodrug means a compound which is converted in vivo into a compound represented by the general formula (I), and such a prodrug is also within the scope of the present invention.
- Various forms of prodrugs are well-known in the art.
- the compound represented by the general formula (I) of the present invention has a carboxy group, a hydrogen atom of the carboxy group and a group such as a lower alkyl group (for example, a methyl group, An ethyl group, a propyl group, an isopropyl group, a butyl group, a tert-butyl group, etc.); a lower acyloxymethyl group (eg, a pivaloyloxymethyl group); a 1- (lower acyloxy) ethyl group (eg, a 11 Lower alkoxyl oxycarbonyl group (eg, tert-butoxycarbonyloxymethyl group); 11 (lower alkoxyloxyloxy) ethyl group (eg, 11-tert-butoxycarboxyl) Niroki Or an ester formed by substitution with a 3-phthalidyl group.
- a lower alkyl group for example, a methyl group, An ethyl
- the compound represented by the general formula (I) of the present invention has a hydroxyl group, a hydrogen atom of the hydroxyl group and a group such as the following: a lower acetyl group (for example, an acetyl group, a propionyl group, Ptyryl group, isoptyryl group, pivalyl group, etc.); lower alkoxyl propyl group (for example, methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, tert-butoxycarbonyl group, etc.); succinoyl group; Lower-acyloxymethyl group (for example, pivaloyloxymethyl group); 1- (lower-oxyloxy) ethyl group (for example, 1- (pivaloyloxy) ethyl group, etc.); Substitution with a methyl group (for example, tert_butoxycarboxyloxymethyl group) Compounds made thereof.
- the compound represented by the general formula (I) of the present invention has an amino group such as —NH or —NH 2 , a hydrogen atom of the amino group and a group represented by the following as a prodrug:
- Lower acetyl group for example, acetyl group, propionyl group, butyryl group, isopyryl group, pivaloyl group, etc.
- lower alkoxycarbonyl group for example, methoxycarbonyl group, ethoxycarbonyl group, propoxycarbyl group, isopropoxycarbonyl group
- Tert-butoxycarbonyl group etc.
- prodrug compounds can be prepared according to a method known per se, for example, TWGreen and PGH Wuts, rprotective Groups in Organic Synthesis], 3rd edition, and the compound represented by the general formula (I) according to the references described therein. Can be manufactured from In the compound represented by the general formula (I),
- R 1 and R 2 are each independently, preferably a hydrogen atom or CI_ 4 lower ⁇ alkyl group, more preferably a hydrogen atom;
- R 3 , R 4 , R 5 and R 6 are each independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, preferably water An atom, a halogen atom or a lower alkyl group, more preferably a hydrogen atom or a lower alkyl group, provided that at least one of R 3 , RR 5 and R 6 is an octogen atom, a lower alkyl group or a lower alkoxy group
- R 3 , RR 5 and R 6 is an octogen atom, a lower alkyl group or a lower alkoxy group
- R 3 , R 4 , R 5 and R 6 are hydrogen atoms
- R 7 and R 8 are each independently preferably a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkoxy group, an aryloxy group, a lower alkylsulfanyl group, a hydroxyl group or a lower acyl group. And more preferably a hydrogen atom, a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, an aryloxy group, a hydroxyl group or a lower acyl group;
- R 9 is preferably —C (0) —R 1 . Or — OCH 2 C ( ⁇ ) -R 10 ; wherein R 1G is preferably a hydroxyl group or a lower alkoxy group.
- a preferred embodiment of the present invention has the general formula (II)
- R 3 , R 4 , R 5 and R 6 are each independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
- R 7 and R s each independently represent a hydrogen atom, a halogen atom, a lower alkyl group, an octa-lower alkyl group, a cycloalkyl group, a lower alkoxy group, an aryloxy group, a lower alkylsulfanyl group, a hydroxyl group, or a lower group.
- R 9 is one C (0) _R 1 () or one CH 2 C ( ⁇ ) —R 10 ;
- R 1Q is a hydroxyl group, a lower alkoxy group or an aralkyloxy group; provided that at least one of R 3 , R 4 , R 5 and R 6 is a halogen atom, a lower alkyl group or a lower alkoxy group.
- R 7 is preferably a hydrogen atom
- R 8 is preferably a hydrogen atom, a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, an aryloxy group, a hydroxyl group or a lower acyl group, more preferably a lower alkyl group, a cycloalkyl group, a lower alkoxy group , An aryloxy group, a hydroxyl group or a lower acyl group, still more preferably a lower alkyl group, a lower alkoxy group, an aryloxy group or a lower acyl group.
- R 4 is preferably a hydrogen atom, a halogen atom or a lower alkyl group
- R 5 is preferably a halogen atom or a lower alkyl group, more preferably R 4 and R 5 are each independently a lower alkyl group Group,
- R 4 and R 6 are a hydrogen atom
- R 3 is preferably ⁇ is a halogen atom or a lower alkyl group
- R 5 is preferably a hydrogen atom, an octane atom or a lower alkyl group.
- Alkyl is a compound of the general formula (III)
- R 3 , R 4 , R 5 and R 6 are each independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
- R 7 and R s each independently represent a hydrogen atom, a halogen atom, a lower alkyl group, an octa-lower alkyl group, a cycloalkyl group, a lower alkoxy group, an aryloxy group, a lower alkylsulfanyl group, a hydroxyl group
- R 9 is one C ( ⁇ ) one R 10 or one OCH 2 C (O) —R 10 , or a lower acyl group;
- R 1Q is a hydroxyl group, a lower alkoxy group or an aralkyloxy group; provided that at least one of R 3 , R 4 , R 5 and R 6 is a halogen atom, a lower alkyl group or a lower alkoxy group.
- R 3 and R 6 are preferably a hydrogen atom
- R 4 is preferably a hydrogen atom or a lower alkyl group
- R 5 is preferably a lower alkyl group
- R 7 is preferably a hydrogen atom
- R 8 is preferably a halogen atom or a lower alkyl group.
- T Yet another preferred embodiment of the present invention has the general formula (IV):
- R 7 and R 8 are each independently a hydrogen atom, an octogen atom .. a lower alkyl group, an octa-lower alkyl group, a cycloalkyl group, a lower alkoxy group or an aryloxy group;
- R 9 is one C (O) —R 10 or —OCH 2 C (O) —R 10
- R 10 is a hydroxyl group, a lower alkoxy group or an aralkyloxy group.
- R 7 is preferably a hydrogen atom
- R 8 is preferably a halogen atom, a lower alkyl group, an octa-lower alkyl group, a cycloalkyl group, a lower alkoxy group or an aryloxy group, more preferably a lower alkyl group, an octa-lower alkyl group or Aryloxy group.
- a specific example of a preferred embodiment of the present invention is a compound selected from the group consisting of: or a lower alkyl ester thereof, or a pharmaceutically acceptable salt thereof.
- R 1 R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined above, and Y 1 is a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyl Represents a leaving group such as an alkoxy group or a ⁇ -toluenesulfonyloxy group)
- An amino alcohol derivative) and an alkylating agent (XI) in an inert solvent eg, ⁇ , ⁇ -dimethylformamide, acetonitrile, etc.
- an inert solvent eg, ⁇ , ⁇ -dimethylformamide, acetonitrile, etc.
- a base eg, By reacting in the presence or absence of N, N-diisopropylethylamine, triethylamine, etc., the compound represented by the general formula (I) can be obtained.
- Compound (I) having a carboxylic acid ester group in R 7 , R 8 , and R 9 can be treated by hydrolysis with an aqueous alkali solution in a suitable solvent (for example, ethanol, etc.), if necessary. Can be converted to ruponic acid.
- Compound (I) having a carbonyl group in R 9 can be prepared by reacting a condensing agent (eg, diphenylphosphoryl azide) in an inert solvent (eg, tetrahydrofuran, methylene chloride, N, N-dimethylformamide, etc.).
- a condensing agent eg, diphenylphosphoryl azide
- an inert solvent eg, tetrahydrofuran, methylene chloride, N, N-dimethylformamide, etc.
- R 3 Q is a hydrogen atom or a lower alkyl group.
- R 3 s form a group represented by —C (CH 3 ) 2 C (CH 3 ) 2 —
- Y 2 is a chlorine atom, a bromine atom, an iodine atom or trifluoromethane Step 2-1 and 2-2
- the compound represented by the general formula (XI II) can be obtained by reacting the amino alcohol derivative (X) with the alkylating agent (XI I) in the same manner as in Step 11-11.
- the compound (I) is reacted with the boronic acid derivative (XIV) in an inert solvent in the presence of a palladium catalyst and a base to give a compound (I).
- a palladium catalyst examples include N, N-dimethylformamide, 1,4-dioxane, toluene and the like.
- the palladium catalyst examples include tetrakis (triphenylphosphine) palladium (0), dichlorobis (triphenylphosphine) palladium (II) and the like.
- the base include cesium fluoride, sodium carbonate and the like. This reaction can be carried out, if necessary, by adding a ligand such as bis (diphenylphosphino) phenene.
- Compound (I) can also be obtained by the following reaction. That is, the compound represented by the general formula (XVI) is obtained by reacting the amino alcohol derivative (X) with the alkylating agent (XV) in the same manner as in the step 1-1. The compound (XVI) is reacted with the compound (XVI I) in the same manner as in Step 2-2 to obtain a compound (I).
- Compound (XVI) is prepared by converting compound (XI II) with bis (pinacolato) dipolone in an inert solvent (eg, N, N-dimethylformamide, 1,4-dioxane, etc.) in the presence of a palladium catalyst and a base. It can also be obtained by reacting.
- a palladium catalyst include dichlorobis (triphenylphosphine) palladium (II).
- the base include potassium acetate. This reaction can be carried out, if necessary, by adding a ligand such as bis (diphenyl phosphino) phenol.
- Step 3-1 (Wherein, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined above).
- the compound represented by the general formula (la) can be obtained by reacting the amino alcohol derivative (X) with the aldehyde derivative (XVIII) in a suitable solvent in the presence of a reducing agent.
- Solvents that can be used in this reductive amination reaction include, for example, ethers such as tetrahydrofuran and 1,4-dioxane, halogenated carbons such as methylene chloride, organic sulfonic acids such as acetic acid, and hydrocarbons such as toluene. , Methanol, alcohols such as ethanol, and acetonitrile. If necessary, two or more of these solvents can be used in combination.
- reducing agent for example, NaBH 4, NaBH 3 CN, NaBH (OAc) 3 aqueous borohydride Al force Li metal such as, BH 3 ⁇ pyridine, BH 3 ⁇ N, N-Jechiruani Pollan such as phosphorus, etc. Is mentioned.
- This reaction can be carried out, if necessary, by adding an acid such as acetic acid, -toluenesulfonic acid, methanesulfonic acid, sulfuric acid, or hydrochloric acid.
- reaction instead of using the above reducing agent, the presence of a catalytic amount of a metal catalyst (for example, 5 to 10% palladium carbon, Raney nickel, platinum oxide, palladium black, 10% platinum carbon (sulfur poisoning), etc.)
- a metal catalyst for example, 5 to 10% palladium carbon, Raney nickel, platinum oxide, palladium black, 10% platinum carbon (sulfur poisoning), etc.
- the reaction can be performed under a hydrogen atmosphere below.
- This reductive amination reaction is performed by selecting appropriate reduction conditions according to the type of the substituent in compound (XVIII).
- R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 3Q and Y 2 are as defined above
- Compound (la) can also be obtained by the following reaction.
- the compound represented by the general formula (XXII) can be obtained by reacting the amino alcohol derivative (X) with the aldehyde (XXI) in the same manner as in Step 3-1.
- This compound (XXII) can also be obtained by reacting compound (XX) with bis (pinacolato) dipolone in the same manner as in step 2-5.
- Compound (la) is obtained by reacting compound (XXII) with compound (XVII) in the same manner as in step 2-2.
- an amide derivative represented by (XXIV) is obtained.
- the condensing agent that can be used in this amidation reaction include diphenylphosphoryl azide, getyl cyanophosphate, 1,3-dicyclohexylcarboimide, and 1,3-[(3- (dimethylamino) propyl] -13-ethylcarbodiimide hydrochloride.
- the amide derivative (XXIV) is obtained by converting a carboxylic acid derivative ( ⁇ ) into an active ester (eg, 4-nitrophenyl ester, 2,5-dioxapyrrolidine ester, etc.) based on a conventional method. It can also be obtained by reacting with a amino alcohol derivative (X).
- an active ester eg, 4-nitrophenyl ester, 2,5-dioxapyrrolidine ester, etc.
- Compound (la) can also be obtained by the following reaction. That is, the compound represented by the general formula (XXVI) is obtained by reacting the amino alcohol derivative (X) with the carboxylic acid (XXV) in the same manner as in Step 5-1. The compound (XXVI) is reduced in the same manner as in Step 5-2 to obtain a compound represented by the general formula (XXI I). This compound (XXII) can also be obtained by reacting compound (XX) in the same manner as in step 2-5. Compound (la) is obtained by reacting compound (XXI I) with compound (XVI I) in the same manner as in Step 2-2.
- the alkylating agents (XI), (XI I) and (XV) can be produced by the method shown in Scheme 6 or 7.
- P h 3 P represents triphenylphosphine
- DEAD represents dialkyl azodicarboxylate
- the compound represented by the general formula (XII) can be obtained by subjecting to a reaction well known to those skilled in the art as a Mitsunobu reaction in the presence of triphenylphosphine and a dialkyl azodicarboxylate.
- a reaction well known to those skilled in the art as a Mitsunobu reaction in the presence of triphenylphosphine and a dialkyl azodicarboxylate.
- dialkyl azodicarboxylate used in the present reaction include acetyl azodicarboxylate, diisopropyl azodicarboxylate, and the like.
- a compound represented by the general formula (XXVIII) is obtained.
- This compound (XXVIII) can also be obtained by reacting the phenol derivative (XXIX) with the compound (XVII) in the same manner as in step 2-2.
- the compound (XXVIII) is reacted with the alcohol derivative (XXX) in the same manner as in Step 6-1 to obtain a compound represented by the general formula (XI).
- Step 6 5 ' Phenol derivative ⁇ ) and alcohol derivative ⁇ ) as in step 6-1
- Step 7-2 Introduction of leaving group Step 4 Introduction of leaving group S Step 7-6 Introduction of leaving group
- R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 30 , Y 1 and Y 2 are as defined above, R 2 Q represents a lower alkyl group, X 1 represents a chlorine atom or a bromine atom)
- This compound (XXXII) can also be obtained by the following reaction . That is, a phenol derivative (XXVI I) and a compound (XXXI) are mixed in an inert solvent (eg, N, N-dimethylformamide, acetonitrile, etc.) in the presence of a base (eg, potassium carbonate, cesium carbonate, etc.). By reacting, phenoxyacetic acid ester is obtained.
- an inert solvent eg, N, N-dimethylformamide, acetonitrile, etc.
- a base eg, potassium carbonate, cesium carbonate, etc.
- the compound (XXXII) is converted to a sulfonyl octylide in an inert solvent (eg, methylene chloride, chloroform) in the presence of a halogenating reagent or a base (eg, N, N-diisopropylethylamine).
- a halogenating reagent include, for example, thionyl chloride. Phosphorus tribromide, triphenylphosphine Z carbon tetrabromide and the like.
- the sulfonyl chloride include .. methanesulfonyl chloride and p-toluenesulfonyl chloride.
- Compound (XXXI II) can also be obtained by reacting compound (XXXI I) with boronic acid derivative (XIV) in the same manner as in Step 2-2. Further, this compound (XXXI II) can also be obtained by reacting compound (XXXIV) with compound (XVI I) in the same manner as in Step 2-2.
- the aldehyde derivatives (XVIII) (XIX) and (XXI) can be produced by the method shown in Scheme 8 or 9.
- the aldehyde derivative represented by the general formula (XIX) can be obtained by oxidizing the alcohol derivative ( ⁇ ) in an inert solvent (eg, methylene chloride) using a suitable oxidizing agent.
- oxidizing agents include, for example, oxalyl chloride Z dimethyl sulfoxide, or 1,1,1-triacetoxy-1,1,1-dihydrofluoride mouth, 1,2-benzido-doxo-l-3 (1H) -one.
- the aldehyde derivative represented by the general formula (XVIII) or (XXI) is obtained by oxidizing the alcohol derivative (XXXIII) or (XXXIV) in the same manner as in Step 8-1.
- the acetal derivative (XXXVI) is hydrolyzed with an acid according to a conventional method to obtain an aldehyde derivative represented by the general formula (XIX).
- the compound represented by the general formula (XXXVIII) is obtained by reacting the compound (XXIX) with the alkylating agent (XXXV) in the same manner as in Step 911. This compound (XXIX)
- Compound (XXXVII) can also be obtained by reacting compound (XXXVI) with boronic acid derivative (XIV) in the same manner as in Step 2-2. Further, this compound (XXXVII) can also be obtained by reacting compound (XXXVIII) with compound (XVII) in the same manner as in Step 2-2. Of the starting materials used in Scheme 5, carboxylic acid derivatives (XXIII) and (XXV) can be produced by the method shown in Scheme 10.
- R 3 , R 4 , R 5 , R 6 , R 20 , R 3 X 1 and Y 2 are as defined above).
- the phenol derivative (XXVII) and the compound (XXXI) are converted into an inert solvent (for example, N , N-dimethylformamide, acetonitrile, etc.) in the presence of a base (eg, potassium carbonate, cesium carbonate, etc.) to give phenoxyacetic acid ester.
- an inert solvent for example, N , N-dimethylformamide, acetonitrile, etc.
- a base eg, potassium carbonate, cesium carbonate, etc.
- the compound represented by the general formula (XXV) is obtained by reacting the phenol derivative (XXIX) in the same manner as in Step 10-1.
- the boronic acid derivative (XIV) used in Schemes 2, 4 and 5 can be synthesized using a commercially available reagent or according to a conventional method.
- compounds (XlVa) and (XlVb) in which R 9 is a lower alkoxycarbonyl group or a hydroxyl group can be produced by the method shown in Scheme 11.
- R 7 , R 8 and R 2 Q are as defined above, Y 3 represents a chlorine atom, a bromine atom or an iodine atom, and B n represents a benzyl group)
- Y 3 represents a chlorine atom, a bromine atom or an iodine atom
- B n represents a benzyl group
- the aryl halide derivative (XXXIX) is lithiated according to a conventional method and reacted with carbon dioxide to obtain a benzoic acid derivative represented by the general formula (LX).
- This compound (LX) can also be obtained by the following reaction. That is, after introducing a formyl group into the aryl derivative (LXI) by a Vilsmeier reaction or the like, a suitable oxidizing agent (eg, tert-butyl alcohol, 2-methyl-2-butene, etc.) is used. Oxidation using, for example, sodium chlorite) can provide a benzoic acid derivative (LX).
- a suitable oxidizing agent eg, tert-butyl alcohol, 2-methyl-2-butene, etc.
- a compound represented by the general formula (XIVa) can be obtained.
- the boronic ester derivative (XIVa) can also be obtained by similarly reacting a halogenated benzoic acid derivative (XVI Ia) with bis (pinacolato) diboron.
- the boronic acid derivative represented by the general formula (XlVb) can be obtained by hydrolyzing this compound (XlVa) using an aqueous solution of Arikari according to a conventional method.
- the arylporonic acid ester derivative (XXXIV) used in Schemes 7 and 8 can also be produced by the method shown in Scheme 12.
- the compound (XXXII) is reacted with a benzyl halide (eg, benzyl bromide) in the presence of a base (eg, sodium hydride, etc.) to give a monobenzyl compound.
- a benzyl halide eg, benzyl bromide
- a base eg, sodium hydride, etc.
- the O-benzyl compound is converted into a Grignard reagent or a lithium compound according to a conventional method, and then reacted with a borate (LXIV) to obtain a compound represented by the general formula (LXV).
- LXIV borate
- the compound (LXV) is debenzylated according to a conventional method, and is hydrolyzed as necessary to obtain a compound represented by the general formula (XXXIV).
- Compound (XXXIV) can also be obtained by the following reaction. That is, the compound represented by the general formula (LXVI) is obtained by reacting the compound (XXXII) with bis (pinacolato) diboron in the same manner as in Step 2-5. Compound (XXXIV) is obtained by hydrolyzing this compound (LXVI) if necessary.
- the compound (XVI Ia) used in Scheme 11 the compound (XVI Ib) wherein Y 3 is a chlorine atom or a bromine atom can be produced by the method shown in Scheme 13.
- R 7 , R 8 and R 2 Q are as defined above, and Y 4 represents a chlorine atom or a bromine atom
- the compound represented by the general formula (LXVI I I) can be obtained by reacting the phenol derivative (LXVI I) with a halogenating agent in a suitable solvent.
- a suitable solvent examples include inorganic acids such as sulfuric acid, organic carboxylic acids such as acetic acid, and halogenated carbons such as methylene chloride.
- the halogenating agent for example, bromine, ⁇ ⁇ ⁇ -chlorosuccinimide, ⁇ -bromosuccinimide-.hydrobromic acid / dimethyl sulfoxide and the like are used.
- the compound (LXVI 1 I) is reacted with trifluoromethanesulfonic anhydride to obtain a to-trifluoromethanesulfonyl compound.
- the O-trifluoromethanesulfonyl compound is reacted with carbon monoxide and R 2 QOH in an inert solvent in the presence of a phosphine ligand, a palladium catalyst and a base to obtain a compound represented by the general formula (XVI Ib).
- Solvents that can be used in this reaction include, for example, N, N-dimethylformamide, dimethyl sulfoxide and the like.
- the phosphine ligand include triphenylphosphine and 1,3-bis (diphenylphosphino) propane.
- the palladium catalyst include palladium acetate.
- Examples of the base include triethylamine.
- the amino alcohol derivative represented by the formula (X) used in the above scheme can be obtained by optically resolving a commercially available enantiomer mixture according to a conventional method, or by a method described in the literature (for example, “J. Med. Chem. J 1977”). Year, Vol. 20, No. 7, p. 978-981).
- the compound represented by the general formula (I) of the present invention and the intermediate used for producing the compound may be, if necessary, isolated and purified by a method known to those skilled in the art. Isolation and purification can be achieved by performing certain operations such as solvent extraction, crystallization, recrystallization, chromatography, and preparative high performance liquid chromatography.
- the compound of the present invention thus produced has a fat decomposing action and / or a heat production promoting action, and is therefore useful as an agent for treating or preventing obesity.
- the compounds of the present invention, if necessary, / 3 3 - in combination with a adrenergic receptor agonists other than anti-obesity agent can be used.
- antiobesity agents include, for example, appetite suppressants.
- Such appetite suppressants include, for example, monoamine reuptake inhibitors, serotonin agonists, dopamine agonists, neuropeptides Y agonites, leptin, or CCK-A (cholecystokinin A) agonists Is mentioned.
- Monoamine reuptake inhibitors used in combination with the compounds of the present invention include, for example, sibutramine, milnacipran, duloxetine, venlafaxine and the like.
- Serotonin agonists used in combination with the compounds of the present invention include, for example, fenfluramine and dexfenfluramine.
- a dopamine agonist used in combination with the compound of the present invention is, for example, promocribtin.
- Neuropeptide Y antagonists used in combination with the compounds of the present invention include, for example, CP 671906-01 and J-115814.
- Examples of lebutin used in combination with the compound of the present invention include human recombinant lebutin.
- CCK used in combination with the compounds of the present invention—A agonist Examples include GW-7178 and SR-146131.
- the compound of the present invention has a hypoglycemic effect and further has an insulin resistance improving effect, and thus is useful as an agent for treating or preventing diabetes, particularly type II diabetes, and diseases caused by diabetes.
- the compounds of the present invention if necessary,] 3 3 - in combination with a adrenergic receptor agonists other than anti-diabetic agents may be used.
- a adrenergic receptor agonists other than anti-diabetic agents
- Such antidiabetic agents include, for example, —glycosidase inhibitors, insulin sensitizers, insulin preparations, insulin secretagogues, biguanides, glucagon-like peptide-11, DPPIV inhibitors, and SGLT inhibitors
- ⁇ -glycosidase inhibitor used in combination with the compound of the present invention include, for example, acarbose, miglitol, and poglibose.
- insulin sensitizers used in combination with the compounds of the present invention include, for example, peodarisuzone, rosiglitazone, englitazone, dalglitazone, isaglitazone, CC-555, GI-262570, and JTT- 501 and the like.
- insulin preparation used in combination with the compound of the present invention include, for example, human insulin synthesized by genetic engineering, and insulin extracted from the stomach of stomach and bush.
- insulin secretagogues used in combination with the compounds of the present invention include, for example, sulfonylrearea agents such as tolpumidamide, chlorpropamide, tolazamide, acetohexamide, glibenclamide, dalipidide and gliclside, and mitiglinide (KAD-1229), nateglinide (AY-4166) and glimepiride (Hoe490).
- sulfonylrearea agents such as tolpumidamide, chlorpropamide, tolazamide, acetohexamide, glibenclamide, dalipidide and gliclside
- mitiglinide KAD-1229
- AY-4166 nateglinide
- Hoe490 glimepiride
- piguanides used in combination with the compound of the present invention include, for example, phenformin, metformin, and butformin.
- Glucagon-like peptide-11 (GLP-1) used in combination with the compound of the present invention includes, for example, GLP-1 (36) amide, GLP-1 (7-36) amide and GLP-1 (7- 37).
- DPPIV dipepUdyl peptidase IV
- Glucagon-like peptide-11 (GLP-1) used in combination with the compound of the present invention includes, for example, GLP-1 (36) amide, GLP-1 (7-36) amide and GLP-1 (7- 37).
- DPPIV dipepUdyl peptidase IV
- Examples of SGLT (Na-dependent glucose cotransporter) inhibitors used in combination with the compound of the present invention include, for example, W001 / 16147, W001 / 68660, W001 / 27128, 001/74834, W001 / 74835, Painting / 28872, WOO 2/44192, W002 / 53573, W002 / 64606, Ver.39, W002 / 68440, 002/98893, EP850948, JP12 / 08004K JP11 / 21243, JP09 / 188625.
- the compound of the present invention has a serum triglyceride lowering effect and a Z or cholesterol lowering effect, and thus is useful as an agent for treating or preventing hyperlipidemia.
- the compounds of the present invention can be used in combination with i3 3 _ adrenergic receptor agonists other than antihyperlipidemic agent.
- antihyperlipidemic agents include, for example, HMG-CoA reductase inhibitors, anion exchange resins, fibrates, MTP inhibitors, CETP inhibitors and ACAT inhibitors.
- HMG-CoA reductase inhibitor used in combination with the compound of the present invention include, for example, pravathintin, simbasthintin, full baththintin, atobasinthin, seribasthin and nisbas. Evening Chin.
- Specific examples of the anion exchange resin used in combination with the compound of the present invention include, for example, cholestyramine and cholestiball.
- Specific examples of the fibrate agent used in combination with the compound of the present invention include, for example, bezafibrate, fenofibrate, gemfibre-mouthed jill, simfibrate, ciprofibrate and clinofibrate.
- MTP microsomal triglyceride transfer protein
- CETP cholesterol ester transfer protein
- ACAT acyl-CoA: cholesterol 0-acyl transferase
- the compound of the present invention exhibits an antidepressant effect by stimulating iS 3 -adrenoceptor in the brain, and thus is useful as an agent for treating or preventing depression.
- the compounds of the present invention have the effect of relaxing the bladder detrusor muscle and increasing the bladder dose, so that dysuria (e.g., dysuria nervosa, neuropathic bladder dysfunction, nocturia, unstable bladder) , Urinary frequency in bladder spasm, chronic cystitis, chronic prostatitis, prostatic hypertrophy, etc. Disease, urinary incontinence, etc.).
- dysuria e.g., dysuria nervosa, neuropathic bladder dysfunction, nocturia, unstable bladder
- Urinary frequency in bladder spasm chronic cystitis, chronic prostatitis, prostatic hypertrophy, etc. Disease, urinary incontinence, etc.
- the compounds of the present invention if necessary,] 3 3 - in combination with a adrenergic receptor agonists other than dysuria treatment can be used.
- a adrenergic receptor agonists other than dysuria treatment for example, anticholinergics, alpha iota - adrenoceptor en evening Gonisu Bok include en evening agonist and potassium channel openers.
- Specific examples of the anticholinergic agent used in combination with the compound of the present invention include, for example, oxyptinin, propiverine, tolteridine and the like.
- ⁇ ⁇ (Neurokinin 1) antagonist used in combination with the compound of the present invention include, for example, TAK-637.
- a power stream channel orb used in combination with the compound of the present invention is, for example, KW-7158.
- the compound of the present invention has an inhibitory action on intestinal motility, diseases derived from the promotion of gastrointestinal tract function (for example, esophageal acacia, gastritis, cholecystitis, ulceritis, peritonitis, infectious enteritis, ulcerative colitis, It is useful as a therapeutic or prophylactic agent for Crohn's disease, irritable bowel syndrome, colorectal diverticulitis, simple diarrhea, etc.).
- diseases derived from the promotion of gastrointestinal tract function for example, esophageal acacia, gastritis, cholecystitis, ulceritis, peritonitis, infectious enteritis, ulcerative colitis.
- compositions of the present invention containing the compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient
- dosage forms include, for example, powders, granules, fine granules, dry syrups, tablets, capsules, injections, solutions, ointments, suppositories, patches, and the like. It is administered parenterally.
- compositions can be prepared using known excipients, disintegrants, binders, lubricants, diluents, buffers, isotonic agents, preservatives, and the like, in accordance with the formulation, depending on the dosage form. It can be prepared by appropriately mixing, diluting and dissolving with pharmaceutical additives such as wetting agents, emulsifiers, dispersants, stabilizers, and dissolution aids.
- the dose of the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof is appropriately determined according to the patient's age, sex, body weight, disease, degree of treatment, and the like. Parenteral administration in the range of about 0.03 mg to about 30 mg / day for adults. In the case of -administration, the dose can be appropriately administered once or several times daily in the range of about 0.003 mg to about 30 mg per adult.
- a compound represented by the general formula (I) of the present invention or a pharmacologically acceptable salt thereof, and-an antiobesity agent other than an adrenergic receptor agonist, an antidiabetic agent, an antihyperlipidemic agent, and Pharmaceuticals in combination with at least one drug selected from the therapeutic agents for dysuria can be administered as a preparation containing these active ingredients together or as a preparation separately prepared from each of these active ingredients. .
- the formulations can be administered separately or simultaneously.
- they are formulated separately they can be mixed at the same time with a diluent at the time of use and administered simultaneously.
- the compound represented by formula (I) of the present invention the human / 3 3 - has potent stimulatory effect on adrenergic receptors. Further, the compounds of the present invention have excellent oral absorbability. Furthermore, the compounds of the present invention, j8 3 - minor compared to adrenergic receptor stimulating effect beta! 1 and / or / 3 2 — only show adrenergic receptor stimulatory activity, which may lead to obesity, diabetes, hyperlipidemia, depression, dysuria, diseases caused by gallstones and hyperbiliary motility, or increased gastrointestinal function It is suitable as an agent for treating or preventing a disease of origin. [Best mode for carrying out the invention]
- Benzyl bromide (0.80 mL) was added to a mixture of benzyl 4-benzoyloxy-2-benzyl benzoate (2.23 g) and cesium carbonate (2.29 g) in N, N-dimethylformamide (10 mL) at room temperature. And stirred at 50 ° C for 3 hours. After adding water to the reaction mixture and extracting with ethyl acetate, the organic layer was washed with water and saturated saline, and dried over anhydrous magnesium sulfate.
- Lithium hydroxide monohydrate (0.092 g) was added to a mixture of the 4-ethoxycarbonyl-2-methoxyphenylporonic acid (0.049 g) in water (lmL) and 1,4-dioxane (lmL). Was added and stirred at room temperature overnight. 2 mo1 / L hydrochloric acid (1.09 mL) was added to the reaction mixture, and the solvent was distilled off under reduced pressure. The obtained residue was washed with water to give the title compound (0.035 g).
- Methanesulfonic acid 2_ [2,6-dimethyl-4-1 (4,4,5,5-tetrame Cyl-1,3,2-dioxaborolan-1-yl) phenoxy] ethyl (0.63 g), 4-((1R, 2S) -2-amino-1-hydroxypropyl) phenol (0. A mixture of 29 g) and N, N-diisopropylethylamine (0.36 mL) in N, N-dimethylformamide (10 mL) was stirred at 80 ° C. overnight.
- the title compound was obtained in the same manner as in Reference Example 25 using 4-promo 2,6-dimethylphenol and acetone in the mouth.
- a mixture of N-amino-1-hydroxypropyl) phenol (1.76 g) and N, N-dimethylformamide (2 OmL) was stirred at 80 ° C for 5 hours.
- Ethyl acetate was added to the reaction mixture, washed with water and saturated saline, and dried over anhydrous magnesium sulfate.
- Example 2 shows the structural formulas and physical properties.
- Example 5 Using 4 monobromo-2-isopropylbenzoic acid, the title compound was obtained as a white amorphous solid in the same manner as in Example 3. Table 1 shows the structural formulas and physical properties.
- Example 5 Using 4 monobromo-2-isopropylbenzoic acid, the title compound was obtained as a white amorphous solid in the same manner as in Example 3. Table 1 shows the structural formulas and physical properties.
- Example 5 shows the structural formulas and physical properties.
- Test compounds are dissolved so as to be 10- 2 M at 50% dimethyl sulfoxide, further D-PBS (-): a 1 x 10- 4 M at (Gibco-BRL LIFE TECHNOLOGIES Co.) and highest dose A 10-fold dilution series was prepared and used as a sample for activity measurement.
- SK- N - MC cells American Type Culture Collection Co., lxl 0 5 cell / mL
- the ratio of the maximum response of each test compound to the maximum response of isoproterenol was calculated as the internal activity (IA).
- IA internal activity
- isoproterenol was used.
- the (R) 13 ′-[[2-[[2- (3-chloromethylphenyl) -12-hydroxyethyl) aminoethyl described in Example 17 of W099 / 65877 Example 17 was used.
- Toxi] — [1,1′-Piphenyl] -13-carboxylic acid was similarly tested. The results are shown in Table 5.
- both ends of the region including the full length of the human / 3i-adrenergic receptor were amplified. After introducing the amplified DNA fragment into the vector for cloning, it is propagated in E. coli. Width.
- the cloned plasmid was incorporated into a protein expression vector pCI-neo (Promega), and the plasmid DNA was extracted and purified, and used for preparing the following expression cells.
- Test compounds are dissolved so as to be 10- 2 M at 50% dimethyl sulfoxide, further D-PBS (-) at creating a 1 0-fold dilution series to a 2 X 10- 4 M the maximum dosage, this
- the sample was used for activity measurement.
- D-PBS (-) After washing twice with 200 L per well, add 3-Isobutyl-1-methylxanthine (SIGMA) ImM in 50 portions each, and allow to stand at room temperature for 5 minutes. C, and incubated for 30 minutes at 5% C0 2 conditions.
- the concentration of cAMP accumulated in the cells was reacted with cAMP-Screen and detected with Microplate Lumi nometer TR717.
- the maximum response of isoproterenol which is a positive control, was defined as 100%, and the concentration of the test compound giving a 50% response was EC 5 . Calculated as a value. The ratio of the maximum response of each test compound to the maximum response of isoproterenol was calculated as the internal activity (IA).
- the bladder of a male ferret (body weight 1100-1400 g) was excised, and a bladder smooth muscle specimen of about 10 cm in length and about 2 imi in width was prepared, and an experiment was performed according to the Magnus method. Specimens were suspended in Krebs-Henseleit solution aerated with a mixture of 95% oxygen and 5% carbon dioxide at 37 ° C and loaded with 1 g. Bladder resting tension was isometrically derived via a tension transducer and recorded on the rectogram. Test compounds were cumulatively added to the Magnus tubes about every 5 minutes. Efficacy evaluation 100% tension of urinary bladder smooth muscle before the test compound treatment, the maximum relaxation time of tension after full Orusukorin 10- 5 M treated with 0%, EC 5 the test compound concentration at which to relax 50%. It was evaluated as a value.
- the atrium of a male SD rat (body weight 250-400 g) was excised, and an experiment was performed according to the Magnus method. Specimens were suspended in Krebs-Henseleit solution aerated with a gas mixture containing 95% oxygen and 5% carbon dioxide at 37 and loaded with 0.5 g. The systolic force was derived isometrically via a tension transducer and recorded on a rectogram via an instantaneous heart rate monitor. Test compounds were added cumulatively into Magnus tubes. Efficacy evaluation, the increased heart rate per minute at the time of isoproterenol 10 one 8 M added as 100%, a test compound concentration when increasing the heart rate per minute 50% EC 5. It was evaluated as a value.
- the uterus of an SD pregnancy rat (21st day of pregnancy) was removed, and a specimen about 5 thighs in length and about 15 thighs was prepared in the longitudinal muscle direction, avoiding the placenta attachment, and tested according to the Magnus method.
- Specimens were suspended in Locker-Ringer solution aerated with a mixture of 95% oxygen and 5% carbon dioxide at 37 ° C and loaded with 0.5 g.
- Uterine motility was derived isometrically via a tension transducer and recorded on the rectogram. The test compound was added to the Magnus tube cumulatively about every 5 minutes.
- the efficacy was evaluated by taking the sum of the uterine contraction height for 5 minutes before the addition of the test compound as 100% and comparing it with the sum of the uterine contraction height for 5 minutes after the addition of the test conjugate at each concentration.
- the compound concentration EC 5. It was evaluated as a value.
- Caco-2 cells (American Type Culture Collection) were subcultured in a culture flask using a culture medium.
- the cells After removing the culture medium before the cells reach confluence, the cells are washed with Hank's balanced salt solution Ca, Mg Free (Invitrogen Life Technologies), washed, and treated with 0.25% trypsin / 1 mM EDTA. Peeled off and collected by centrifugation. The cells were resuspended in a culture medium to prepare 1.18 ⁇ 10 5 cells / mU. Transwell the cells with a collagen-coated membrane filter (3 / im pores, 0.33 cm 2 growth area). were seeded in cell culture chamber (Costar Corp.), 5% C0 2, and cultured in a humidified under 37 ° C in Kyube evening within one. After culturing for 21 to 25 days, the membrane resistance was measured with MilliceU-ERS (Millipore), and those having a resistance of 250 ⁇ ⁇ cm 2 or more were used for a drug permeability test.
- MilliceU-ERS MilliceU-ERS
- the membrane permeability coefficient was calculated by the following equation. That is, the amount of drug in the collected buffer solution on the outside side was divided by time, and the amount of permeated drug per unit time (second) was divided by the concentration of added drug and the membrane surface area.
- Drug quantification was performed by LC / MS / MS under the following conditions.
- Ionization method Electrospray method (ESI) Detection: The mass of [M + H] + , the molecular weight of each compound + 1 , was detected, and the analysis was performed using ion generated by fragmentation using nitrogen gas.
- Athenol used as a positive control is a standard compound with a human gastrointestinal absorption rate of about 50%. Since the compound of the present invention exhibited a better permeability coefficient than atenolol, it is expected that the compound of the present invention has sufficient oral absorption in humans.
- Test example 4
- Adipose tissue surrounding epididymis of ddY mouse was excised, and cultured at 37 ° C (33 ⁇ 4 BSA, 1.2 mM CaCl 2 , Krebs-Henseleit solution containing 25 mM HEPES without baking soda, H 7. In 4), the cells were separated into single cells by collagenase (typel, lmg / ml). After washing the cells with the culture solution, the cells were seeded on a 96-well culture plate at 50,000 cells / well and cultured at 37 ° C in the presence of various concentrations of the test compound. Two hours later, the concentration of free fatty acids in the culture solution was measured and used as an index of lipolysis.
- the free fatty acid concentration was measured using NEFA C-Test Co. (Wako Pure Chemical Industries). Efficacy evaluation, the free fatty acid concentrations of isoproterenol 10- 6 M added conditions as 100%, was evaluated the measured test compound concentration of free fatty acids concentration corresponding to 50% as EC 5 0 value.
- the compound of the present invention was orally administered to ddY mice (SLC) at any suitable dose ranging from IgZkg to 10OmgZkg. After a certain period of time, blood was collected, the concentration of free fatty acids in the blood was measured using NEFA C-Test II (Wako Pure Chemical Industries), and the rectal temperature was measured using a digital thermometer.
- the effect of the compound of the present invention on blood glucose, plasma insulin, plasma neutral fat, free fatty acid and glucose tolerance can be evaluated as follows. . That is, the compound of the present invention is administered to KK-Ay / Takl mice (CLEA Japan) at an appropriate dose of 1 g / kg to 100 mg Z kg once or twice a day for several weeks or months. Administer by gavage or orally in a diet. Measure body weight and food consumption throughout the treatment period You. Blood is collected the day before the end of the administration period and the biochemical parameters are measured. Biochemical parameters include blood sugar levels, plasma insulin levels, plasma triglycerides, and free fatty acids. In addition, a transglucose tolerance test is performed on the day following the end of the administration period, and changes over time in blood glucose and plasma insulin are measured, and a glucose tolerance test is performed. Test example 7
- first and / 3 2 of the present invention compounds - the presence or absence of Adorenarin receptor stimulating effect, their respective heart rate and examined the fluctuation of blood pressure as an index.
- a polyethylene catheter filled with heparinized saline was inserted into the carotid artery of an SD rat (SLC) under urethane anesthesia.
- the other end of the catheter was connected to a pressure transducer and blood pressure was measured via an amplifier.
- Heart rate was measured with a counter connected to the amplifier.
- the compound of the present invention was dissolved in an appropriate solvent and intravenously administered to an SD rat from a minimum dose of 10 II g / kg to a maximum dose of 1 mgZkg.
- blood pressure and heart rate after a certain period of time after administration of the test drug were measured and compared with the values before administration. All were extremely minor changes.
- the compound of the present invention was dissolved in an appropriate solvent, and intravenously administered from a minimum dose of 1 ng / kg to a maximum dose of 1 Omg / kg to a power quisar under pentovalpital anesthesia.
- blood pressure and heart rate after a certain period of time after administration of the test drug were measured and compared with the values before administration.
- changes in blood pressure and heart rate were very minor, as in rats.
- the compound represented by the above general formula (I) of the present invention has a strong stimulating action on human / 3 3 -adrenoceptor, it is obese, diabetic, hyperlipidemic, depressive, dysuric. It is suitable as an agent for treating or preventing a disease derived from gallstones and hyperbiliary motility, or a disease derived from increased digestive tract function.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004212381A AU2004212381B2 (en) | 2003-02-14 | 2004-01-30 | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
EP04706789A EP1593666B1 (en) | 2003-02-14 | 2004-01-30 | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
US10/545,380 US7423185B2 (en) | 2003-02-14 | 2004-01-30 | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
JP2005504940A JP4567596B2 (ja) | 2003-02-14 | 2004-01-30 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
CA2514114A CA2514114C (en) | 2003-02-14 | 2004-01-30 | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
BR0407386-0A BRPI0407386A (pt) | 2003-02-14 | 2004-01-30 | Derivados de álcool de amino, composições farmacêuticas contendo os mesmos e uso destes |
DE602004014727T DE602004014727D1 (de) | 2003-02-14 | 2004-01-30 | Aminoalkoholderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verwendung davon |
MXPA05008587A MXPA05008587A (es) | 2003-02-14 | 2004-01-30 | Derivados de alcohol amino, composiciones farmaceuticas que contienen los mismos, y usos de los mismos. |
HK06110137.7A HK1089746A1 (en) | 2003-02-14 | 2006-09-13 | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-035847 | 2003-02-14 | ||
JP2003035847 | 2003-02-14 | ||
JP2003-041931 | 2003-02-20 | ||
JP2003041931 | 2003-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004072016A1 true WO2004072016A1 (ja) | 2004-08-26 |
Family
ID=32871182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000893 WO2004072016A1 (ja) | 2003-02-14 | 2004-01-30 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
Country Status (14)
Country | Link |
---|---|
US (2) | US7423185B2 (ja) |
EP (1) | EP1593666B1 (ja) |
JP (2) | JP4567596B2 (ja) |
KR (1) | KR20050100681A (ja) |
AT (1) | ATE399755T1 (ja) |
AU (1) | AU2004212381B2 (ja) |
BR (1) | BRPI0407386A (ja) |
CA (1) | CA2514114C (ja) |
DE (1) | DE602004014727D1 (ja) |
ES (1) | ES2308142T3 (ja) |
HK (1) | HK1089746A1 (ja) |
MX (1) | MXPA05008587A (ja) |
TW (1) | TWI319316B (ja) |
WO (1) | WO2004072016A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040093A1 (ja) * | 2003-10-24 | 2005-05-06 | Kissei Pharmaceutical Co., Ltd. | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
WO2005061433A2 (en) * | 2003-12-23 | 2005-07-07 | Astellas Pharma Inc. | Aminoalcohol derivatives |
WO2006022237A1 (ja) * | 2004-08-24 | 2006-03-02 | Kissei Pharmaceutical Co., Ltd. | 脂肪肝の予防または治療剤 |
WO2006115154A1 (ja) * | 2005-04-22 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | 4´-{2-[(1s,2r)-2-ヒドロキシ-2-(4-ヒドロキシフェニル)-1-メチルエチルアミノ]エトキシ}-3-イソプロピル-3´,5´-ジメチルビフェニルカルボン酸塩酸塩の結晶多形 |
WO2006123672A1 (ja) | 2005-05-19 | 2006-11-23 | Kissei Pharmaceutical Co., Ltd. | ビフェニル基を有するアミノアルコール誘導体の製造方法 |
WO2007026630A1 (ja) | 2005-08-29 | 2007-03-08 | Kissei Pharmaceutical Co., Ltd. | 涙液の減少に伴う疾患の予防又は治療剤 |
WO2007061114A1 (ja) * | 2005-11-28 | 2007-05-31 | Kissei Pharmaceutical Co., Ltd. | 神経因性疼痛の予防又は治療用医薬組成物 |
US7579507B2 (en) | 2005-04-22 | 2009-08-25 | Kissei Pharmaceutical Co., Ltd. | Polymorphic crystal of 4′-{2-[ (1S, 2R)—2- hydroxy-2- (4-hydroxyphenyl)-1-methylethylamino]ethoxy} - 3 - isopropyl-3′, 5′ -dimethylbiphenyl- 4 - carboxylic acid hydrochloride |
WO2012013691A1 (en) | 2010-07-28 | 2012-02-02 | Prous Institute For Biomedical Research, S.A. | Multitarget substituted biphenyl diol derivatives |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05008587A (es) * | 2003-02-14 | 2005-11-04 | Kissei Pharmaceutical | Derivados de alcohol amino, composiciones farmaceuticas que contienen los mismos, y usos de los mismos. |
US20070111981A1 (en) * | 2005-10-26 | 2007-05-17 | Roth Gerald J | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds |
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
MX2015016543A (es) * | 2013-06-27 | 2017-07-27 | Lg Chemical Ltd | Derivados de biarilo como agonistas de gpr120. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4130918A1 (de) * | 1991-09-17 | 1993-03-18 | Juergen Dr Huhnt | Arzneimittel zur unterbrechung der vasokonstriktion nach gabe von lokalanaesthetika mit vasokonstriktorischer wirkung |
EP0882707A1 (en) * | 1996-01-10 | 1998-12-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel tricyclic compounds and drug compositions containing the same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3124242B2 (ja) * | 1996-01-10 | 2001-01-15 | 旭化成工業株式会社 | 新規な3環性化合物 |
DE69919860T2 (de) | 1998-04-14 | 2005-08-25 | Kissei Pharmaceutical Co., Ltd., Matsumoto | 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen |
GB9812709D0 (en) * | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
WO2002094770A2 (en) * | 2001-05-24 | 2002-11-28 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
US6864268B2 (en) * | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
MXPA05008587A (es) * | 2003-02-14 | 2005-11-04 | Kissei Pharmaceutical | Derivados de alcohol amino, composiciones farmaceuticas que contienen los mismos, y usos de los mismos. |
WO2005040093A1 (ja) * | 2003-10-24 | 2005-05-06 | Kissei Pharmaceutical Co., Ltd. | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
CA2551167C (en) | 2003-12-23 | 2011-10-18 | Astellas Pharma Inc. | Aminoalcohol derivatives |
-
2004
- 2004-01-30 MX MXPA05008587A patent/MXPA05008587A/es active IP Right Grant
- 2004-01-30 WO PCT/JP2004/000893 patent/WO2004072016A1/ja active IP Right Grant
- 2004-01-30 BR BR0407386-0A patent/BRPI0407386A/pt not_active IP Right Cessation
- 2004-01-30 EP EP04706789A patent/EP1593666B1/en not_active Expired - Lifetime
- 2004-01-30 AT AT04706789T patent/ATE399755T1/de not_active IP Right Cessation
- 2004-01-30 CA CA2514114A patent/CA2514114C/en not_active Expired - Fee Related
- 2004-01-30 US US10/545,380 patent/US7423185B2/en not_active Expired - Fee Related
- 2004-01-30 KR KR1020057014881A patent/KR20050100681A/ko active IP Right Grant
- 2004-01-30 DE DE602004014727T patent/DE602004014727D1/de not_active Expired - Lifetime
- 2004-01-30 ES ES04706789T patent/ES2308142T3/es not_active Expired - Lifetime
- 2004-01-30 JP JP2005504940A patent/JP4567596B2/ja not_active Expired - Fee Related
- 2004-01-30 AU AU2004212381A patent/AU2004212381B2/en not_active Ceased
- 2004-02-13 TW TW093103476A patent/TWI319316B/zh not_active IP Right Cessation
-
2006
- 2006-09-13 HK HK06110137.7A patent/HK1089746A1/xx not_active IP Right Cessation
-
2007
- 2007-11-07 US US11/936,680 patent/US7674938B2/en not_active Expired - Fee Related
-
2010
- 2010-06-23 JP JP2010142134A patent/JP2010285433A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4130918A1 (de) * | 1991-09-17 | 1993-03-18 | Juergen Dr Huhnt | Arzneimittel zur unterbrechung der vasokonstriktion nach gabe von lokalanaesthetika mit vasokonstriktorischer wirkung |
EP0882707A1 (en) * | 1996-01-10 | 1998-12-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel tricyclic compounds and drug compositions containing the same |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4644601B2 (ja) * | 2003-10-24 | 2011-03-02 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
WO2005040093A1 (ja) * | 2003-10-24 | 2005-05-06 | Kissei Pharmaceutical Co., Ltd. | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
JPWO2005040093A1 (ja) * | 2003-10-24 | 2007-03-08 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
US7417169B2 (en) | 2003-10-24 | 2008-08-26 | Kissei Pharmaceutical Co., Ltd. | Amino alcohol derivatives, medicinal composition containing the same, and use of these |
JP2007516211A (ja) * | 2003-12-23 | 2007-06-21 | アステラス製薬株式会社 | アミノアルコール誘導体 |
WO2005061433A2 (en) * | 2003-12-23 | 2005-07-07 | Astellas Pharma Inc. | Aminoalcohol derivatives |
WO2005061433A3 (en) * | 2003-12-23 | 2005-10-27 | Astellas Pharma Inc | Aminoalcohol derivatives |
US7417060B2 (en) | 2003-12-23 | 2008-08-26 | Astellas Pharma Inc. | Aminoalcohol derivatives |
WO2006022237A1 (ja) * | 2004-08-24 | 2006-03-02 | Kissei Pharmaceutical Co., Ltd. | 脂肪肝の予防または治療剤 |
US7579507B2 (en) | 2005-04-22 | 2009-08-25 | Kissei Pharmaceutical Co., Ltd. | Polymorphic crystal of 4′-{2-[ (1S, 2R)—2- hydroxy-2- (4-hydroxyphenyl)-1-methylethylamino]ethoxy} - 3 - isopropyl-3′, 5′ -dimethylbiphenyl- 4 - carboxylic acid hydrochloride |
WO2006115154A1 (ja) * | 2005-04-22 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | 4´-{2-[(1s,2r)-2-ヒドロキシ-2-(4-ヒドロキシフェニル)-1-メチルエチルアミノ]エトキシ}-3-イソプロピル-3´,5´-ジメチルビフェニルカルボン酸塩酸塩の結晶多形 |
WO2006123672A1 (ja) | 2005-05-19 | 2006-11-23 | Kissei Pharmaceutical Co., Ltd. | ビフェニル基を有するアミノアルコール誘導体の製造方法 |
WO2007026630A1 (ja) | 2005-08-29 | 2007-03-08 | Kissei Pharmaceutical Co., Ltd. | 涙液の減少に伴う疾患の予防又は治療剤 |
WO2007061114A1 (ja) * | 2005-11-28 | 2007-05-31 | Kissei Pharmaceutical Co., Ltd. | 神経因性疼痛の予防又は治療用医薬組成物 |
WO2012013691A1 (en) | 2010-07-28 | 2012-02-02 | Prous Institute For Biomedical Research, S.A. | Multitarget substituted biphenyl diol derivatives |
EP2423181A1 (en) | 2010-07-28 | 2012-02-29 | Prous Institute For Biomedical Research S.A. | Multitarget substituted biphenyl diol derivatives |
Also Published As
Publication number | Publication date |
---|---|
TW200418448A (en) | 2004-10-01 |
DE602004014727D1 (de) | 2008-08-14 |
CA2514114A1 (en) | 2004-08-26 |
EP1593666A1 (en) | 2005-11-09 |
TWI319316B (en) | 2010-01-11 |
AU2004212381A1 (en) | 2004-08-26 |
JP4567596B2 (ja) | 2010-10-20 |
EP1593666B1 (en) | 2008-07-02 |
HK1089746A1 (en) | 2006-12-08 |
US20060128807A1 (en) | 2006-06-15 |
AU2004212381B2 (en) | 2008-08-21 |
MXPA05008587A (es) | 2005-11-04 |
BRPI0407386A (pt) | 2006-02-07 |
EP1593666A4 (en) | 2006-10-18 |
JPWO2004072016A1 (ja) | 2006-06-01 |
JP2010285433A (ja) | 2010-12-24 |
US7674938B2 (en) | 2010-03-09 |
CA2514114C (en) | 2011-03-15 |
ATE399755T1 (de) | 2008-07-15 |
ES2308142T3 (es) | 2008-12-01 |
US7423185B2 (en) | 2008-09-09 |
US20080249177A1 (en) | 2008-10-09 |
KR20050100681A (ko) | 2005-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010285433A (ja) | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 | |
TWI290556B (en) | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | |
CN110049984B (zh) | 苯基丙酸衍生物及其用途 | |
KR101396606B1 (ko) | 신규 갑상선 호르몬 β 수용체 작동약 | |
WO2000002846A1 (en) | Phenoxyacetic acid derivatives and medicinal compositions containing the same | |
WO2005051373A1 (ja) | 受容体機能調節剤 | |
TW200526549A (en) | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | |
JP2022513449A (ja) | 新規な甲状腺模倣物 | |
JP4644601B2 (ja) | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 | |
WO1999031045A1 (fr) | Derives d'acide phenylaminoalkylcarboxylique et compositions medicamenteuses les contenant | |
WO2004108674A1 (ja) | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 | |
JPWO2006022237A1 (ja) | 脂肪肝の予防または治療剤 | |
JPWO2004106290A1 (ja) | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 | |
CN100418944C (zh) | 氨基醇衍生物、含有所述氨基醇衍生物的药物组合物及其应用 | |
WO2014190942A1 (zh) | 一类吲哚类化合物、其制备方法、药物组合物及应用 | |
WO2004106283A1 (ja) | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 | |
Cioroianu et al. | Synthesis and characterization of some new acyl-oximines derivatives | |
JP2002348277A (ja) | ヒドロキシエトキシベンズアミド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504940 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2514114 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3452/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004212381 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006128807 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/008587 Country of ref document: MX Ref document number: 2004706789 Country of ref document: EP Ref document number: 1020057014881 Country of ref document: KR Ref document number: 10545380 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048042352 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2004212381 Country of ref document: AU Date of ref document: 20040130 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004212381 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057014881 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004706789 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0407386 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10545380 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004706789 Country of ref document: EP |